Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

Standard treatment for diffuse large cell lymphoma (DLBCL) with rituximab cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is curative in the majority of patients with low risk di...